441798-33-0

Macitentan (ACT-064992) is an endothelin receptor antagonist utilized in the treatment of pulmonary arterial hypertension (PAH).

Macitentan n-butyl analogue, a derivative of Macitentan, functions as an orally active dual antagonist targeting both endothelin ETA and ETB receptors. This compound shows promise for treating idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH), leveraging its non-peptide structure for potential therapeutic applications.

Macitentan-D4 is a deuterated substitute for Macitentan (T2561) and can be used as a dual antagonist of the non-peptides ETA and ETB (endothelin receptor).Macitentan-D4 is less toxic than Macitentan, has a longer half-life, and can be used to study endothelin receptor-mediated diseases.

Macitentan-[13C2, D4] (Standard) is a reference standard of Macitentan-[13C2, D4] intended for quantitative analysis, quality control, and related biochemical research applications.